Olympus Corporation (Japan) to acquire 100% of Taewoong Medical for KRW 488bn
- Deal value
- $337m
- Stake
- 100%
- Implied 100%
- $337m
- Revenue
- $47m
- Op. income
- $7m
- Multiples
- EQV/EBIT 49.8xPSR 7.1x
Deal value ÷ stake (structure unconfirmed)
2022 별도 · DART-verified
2022 별도 · DART-verified
On implied equity value
DART 20230403001177
- Target
- Taewoong Medical · Gastrointestinal stents (medical devices)
- Buyer
- Olympus Corporation (Japan) · SI
- Seller
- Existing shareholders
- Structure
- —
- Announced
- Feb 24, 2023
- Closed
- —
- Stage
- Signed
Target
Taewoong Medical is a Korean medical device company focused on developing and manufacturing metal stents for gastroenterology (biliary, esophageal, colonic and duodenal). It became a subsidiary within Olympus's Therapeutic Solutions division in January 2024.
Deal rationale
Olympus said the acquisition would strengthen its endoscopic therapeutic solutions portfolio and, per KED Global, enable introduction of a wide range of GI-related products. At closing, Therapeutic Solutions head Gabriela Kaynor called it an important milestone in Olympus's commitment to clinically differentiated solutions for GI patients and said it would expand the GI product lineup globally. Consideration totaled USD 370 million: about USD 255.5 million at completion and USD 114.5 million later.
| Revenue | $47m |
| Operating income | $7m |
| EBITDA | — |
| Net income | — |
2022 별도 · DART-verified · 20230403001177
Press coverage
- KED Global (2023-02-27): “Taewoong Medical acquired by Olympus for $370 million”
- 쿠키뉴스 (2023-02-24): “3억7000만 달러(약 4880억 원)”
- 메디칼타임즈 (2023-02): “총 3억7000만 달러(한화 약 4824억 원)”
- 메디게이트뉴스 (2024-01-25): “이번 인수 규모는 총 3억 7000만 달러이며, 공정거래위원회의 기업결합 심사도 완료했다.”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.